top of page
Untitled design (34).png

OPTIMAL TREATMENT OF RETINAL DISEASE LEVERAGING NOVEL DELIVERY TECHNOLOGY

start
16.png
23.png
Everads: more effective, durable treatment for retinal diseases.
Our technology facilitates targeted, rapid delivery of therapy via the emerging suprachoroidal delivery route. Leveraging our technology, we are developing treatments to improve efficacy and reduce treatment burden, and also partnering with leading pharmaceutical and biotech companies to enable delivery of novel therapies using our technology.
About Everads
Everads is an emerging startup with novel delivery technology to treat retinal diseases via suprachoroidal administration and is developing an early-stage pipeline that leverages our technology.  Our technology enables delivery of therapy to the choroid and retina via the suprachoroidal space (SCS)…. 
about
 Everads News

January 2023

VivaVision and Everads Collaborate to Develop Durable and Effective Therapies for Retinal Diseases. 

Delivery of VivaVision's best-in-class molecules via the suprachoroidal space using Everads' technology is expected to lead to novel treatments for retinal diseases.

shutterstock_2146877303.jpg

January 2023

We are delighted to attend The Next Generation Ophthalmic Drug Delivery Summit. Join us to discover Everads’ novel delivery technology optimizing the treatment of retinal disease.

1.jpg

September 2022

Everads Therapy Featured at the 3rd Annual Gene Therapy for Ocular Disorders Conference

Everads Therapy announced today that Dr. Yoreh Barak, Director of Vitro-Retina Service at Rambam Medical Center, was invited to present Everads’ suprachoroidal delivery technology at the 3rd Annual Gene Therapy for Ocular Disorders conference held September 13-16th in Boston, Massachusetts. 

צילום מסך 2022-11-07 ב-7.06.31.png
Contact Us

Send us a message and we’ll get back to you shortly.

Thanks for submitting!

NEWS HOME
cntact form
bottom of page